Cargando…
Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach
PURPOSE: To compare characteristics of patients, the risk of recurrence, and mortality among adult patients with primary resectable gastrointestinal stromal tumor (GIST) receiving short-term (6–12 months) versus long-term (≥ 24 months) imatinib therapy. METHODS: Detailed information on primary resec...
Autores principales: | Conley, Anthony Paul, Guérin, Annie, Sasane, Medha, Gauthier, Geneviève, Schwiep, Frances, Keir, Christopher Hunt, Wu, Eric Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636436/ https://www.ncbi.nlm.nih.gov/pubmed/23229801 http://dx.doi.org/10.1007/s12029-012-9467-1 |
Ejemplares similares
-
Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013) -
Long-Surviving Patients with Recurrent GIST after Receiving Cytoreductive Surgery with Imatinib Therapy
por: Choi, Won Hyuk, et al.
Publicado: (2009) -
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007) -
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010) -
Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)